🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.3871
-0.0228 (-5.56%)
At close: Nov 19, 2026, 4:00 PM EST
0.4000
+0.0129 (3.33%)
After-hours: Nov 19, 2026, 7:30 PM EST

Coherus Oncology Statistics

Total Valuation

CHRS has a market cap or net worth of $59.82 million. The enterprise value is $45.74 million.

Market Cap59.82M
Enterprise Value 45.74M

Important Dates

The last earnings date was Monday, November 9, 2026, after market close.

Earnings Date Nov 9, 2026
Ex-Dividend Date n/a

Share Statistics

CHRS has 154.54 million shares outstanding. The number of shares has increased by 22.26% in one year.

Current Share Class 154.54M
Shares Outstanding 154.54M
Shares Change (YoY) +22.26%
Shares Change (QoQ) +0.10%
Owned by Insiders (%) 4.25%
Owned by Institutions (%) 48.55%
Float 147.93M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.10
Forward PS 0.77
PB Ratio 2.51
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.84
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 2.75.

Current Ratio 1.51
Quick Ratio 1.29
Debt / Equity 2.75
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -15.24

Financial Efficiency

Return on equity (ROE) is -275.17% and return on invested capital (ROIC) is -1,392.96%.

Return on Equity (ROE) -275.17%
Return on Assets (ROA) -26.43%
Return on Invested Capital (ROIC) -1,392.96%
Return on Capital Employed (ROCE) -152.31%
Weighted Average Cost of Capital (WACC) 10.48%
Revenue Per Employee $369,924
Profits Per Employee -$937,483
Employee Count145
Asset Turnover 0.16
Inventory Turnover 4.71

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -68.01% in the last 52 weeks. The beta is 1.05, so CHRS's price volatility has been similar to the market average.

Beta (5Y) 1.05
52-Week Price Change -68.01%
50-Day Moving Average 0.99
200-Day Moving Average 1.43
Relative Strength Index (RSI) 23.71
Average Volume (20 Days) 2,792,301

Short Selling Information

The latest short interest is 12.71 million, so 8.23% of the outstanding shares have been sold short.

Short Interest 12.71M
Short Previous Month 12.45M
Short % of Shares Out 8.23%
Short % of Float 8.59%
Short Ratio (days to cover) 8.04

Income Statement

In the last 12 months, CHRS had revenue of $53.64 million and -$135.94 million in losses. Loss per share was -$0.96.

Revenue53.64M
Gross Profit 37.45M
Operating Income -145.41M
Pretax Income -155.50M
Net Income -135.94M
EBITDA -141.92M
EBIT -145.41M
Loss Per Share -$0.96
Full Income Statement

Balance Sheet

The company has $83.63 million in cash and $69.55 million in debt, with a net cash position of $14.08 million or $0.09 per share.

Cash & Cash Equivalents 83.63M
Total Debt 69.55M
Net Cash 14.08M
Net Cash Per Share $0.09
Equity (Book Value) 25.25M
Book Value Per Share 0.16
Working Capital 38.49M
Full Balance Sheet

Cash Flow

Operating Cash Flow -173.71M
Capital Expenditures n/a
Depreciation & Amortization 3.49M
Net Borrowing 11.88M
Free Cash Flow -173.71M
FCF Per Share -$1.12
Full Cash Flow Statement

Margins

Gross margin is 69.81%, with operating and profit margins of -271.09% and -253.43%.

Gross Margin 69.81%
Operating Margin -271.09%
Pretax Margin -289.91%
Profit Margin -253.43%
EBITDA Margin -264.58%
EBIT Margin -271.09%
FCF Margin n/a

Dividends & Yields

CHRS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -22.26%
Shareholder Yield -22.26%
Earnings Yield -247.82%
FCF Yield -294.18%

Analyst Forecast

The average price target for CHRS is $7.25, which is 1,772.90% higher than the current price. The consensus rating is "Buy".

Price Target $7.25
Price Target Difference 1,772.90%
Analyst Consensus Buy
Analyst Count 6
Revenue Growth Forecast (3Y) 49.55%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

CHRS has an Altman Z-Score of -13.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -13.44
Piotroski F-Score 3